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Abstract
The identification of galectin-7 as a p53-induced gene and its ability to induce apoptosis in many cell types support the
hypothesis that galectin-7 has strong antitumor activity. This has been well documented in colon cancer. However, in some
cases, such as breast cancer and lymphoma, its high expression level correlates with aggressive subtypes of cancer,
suggesting that galectin-7 may have a dual role in cancer progression. In fact, in breast cancer, overexpression of galectin-7
alone is sufficient to promote metastasis to the bone and lung. In the present work, we investigated the expression and
function of galectin-7 in melanoma. An analysis of datasets obtained from whole-genome profiling of human melanoma
tissues revealed that galectin-7 mRNA was detected in more than 90% of biopsies of patients with nevi while its expression
was more rarely found in biopsies collected from patients with malignant melanoma. This frequency, however, was likely
due to the presence of normal epidermis tissues in biopsies, as shown our studies at the protein level by
immunohistochemical analysis. Using the experimental melanoma B16F1 cell line, we found that melanoma cells can
express galectin-7 at the primary tumor site and in lung metastasis. Moreover, we found that overexpression of galectin-7
increased the resistance of melanoma cells to apoptosis while inducing de novo egr-1 expression. Overexpression of
galectin-7, however, was insufficient to modulate the growth of tumors induced by the subcutaneous injection of B16F1
cells. It also failed to modulate the dissemination of B16F1 cells to the lung.
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Introduction
Melanoma accounts for 4% of dermatological cancers but is
responsible for 80% of mortalities related to skin cancer [1]. In
addition, its incidence is increasing at a higher rate than other
cancer types. Most melanomas are resistant to chemotherapy and
immunotherapy, most likely as a result of resistance to apoptosis
[2,3]. Systemic treatments include the administration of nonspe-
cific immune-stimulating cytokines, immunization with cancer
cells or molecules, adoptive T cell transfer, small inhibitors of
melanoma oncogenes and blocking antibodies against inhibitory
immune molecules, like Ipilimumab [4]. Therefore, it is of great
interest to identify new, relevant biological targets to discover new
therapeutics against melanoma.
Galectins are a family of 15 animal lectins with a unique
carbohydrate recognition domain that binds to b-galactoside
derivatives [5,6]. They can have intracellular (cytoplasmic and/or
nuclear) or extracellular functions, even without a signal sequence,
which is essential for the classical secretory pathway [7,8].
Galectins function during embryonic development, wound heal-
ing, apoptosis, protein trafficking, intercellular adhesion, cell
migration, immune responses and cancer [9–11]. Galectin-1 and
galectin-3 are the most well studied members of the galectin
family, but evidence has shown that other galectins are also
important and have specific expression patterns. This is true for
galectin-7, which was initially described as a marker for
keratinocytes [12,13]. In normal tissues, the expression of
galectin-7 is normally confined to stratified epithelia [14]. In
epithelial cancer, however, its expression is often significantly
altered and may have distinct implications. In a model of human
colon carcinoma, for instance, the exogenous expression of
galectin-7 aids in eliminating tumor cells through its pro-apoptotic
function [15]. This connection between galectin-7 and apoptosis is
supported by studies showing that galectin-7 is induced in human
colon cancer cells following activation of the p53 pathway [16].
Galectin-7 is also associated with the sensitivity of human cervical
carcinoma cells to apoptosis induced by chemotherapeutic agents
[17]. However, galectin-7 has been associated with cancer
progression in chemically induced models of rat mammary
carcinoma [18] and human hypopharyngeal squamous cell
carcinoma [19]. Moreover, galectin-7 overexpression in murine
lymphoma and breast cancer cells has been shown to increase
their ability to metastasize [20–22]. This dual role in controlling
tumor growth is not unusual for members of the galectin family;
for example, it has been well documented for galectin-3 [9,23]. In
the present work, we have investigated the expression pattern of
galectin-7 in melanoma and used a well-characterized melanoma
model to study its functional relevance.
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Materials and Methods
Mice
Breeder pairs for a C57BL/6 mouse colony were purchased
from Jackson Laboratory (Bar Harbor, ME). Galectin-7-deficient
mice (KOG7) in a C57BL/6 background have been described
previously [24]. Male and female mice were bred in our animal
facility and maintained under specific pathogen–free conditions in
accordance with institutional guidelines. All animal studies were
approved by the Institutional Animal Care and Use Committee
(CISAU) of the INRS-Institut Armand-Frappier.
Figure 1. Galectin-7 expression in human melanoma tissues. A) Percentage of positive biopsies of normal skin (n = 7), nevus (n = 18) and
malignant melanoma (n = 45), as determined by the in silico analysis of galectin-7 expression from a microarray of human biopsies [26]. B)
Representative graph of galectin-7 mRNA expression in each biopsy described in (A). C) Detection of galectin-7 by immunohistochemistry in
representative biopsies of nevi and malignant melanoma. Overall, 13 malignant melanomas and 47 nevi were tested.
doi:10.1371/journal.pone.0063307.g001
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Cell Lines and Reagents
The mouse melanoma B16F1 cell line was obtained from the
American Type Culture Collection (ATCC). The aggressive
variant B16F10 cell line was a generous gift from Dr. Alain
Lamarre (INRS-Institut Armand-Frappier) [25]. The human
melanoma cell lines (888mel, 537mel, SK23 and Mel-FB) were a
generous gift from Dr. Re´jean Lapointe (Research Centre, Centre
Hospitalier de l’Universite´ de Montre´al (CRCHUM)) [26]. The
mouse thymic lymphoma line 164T2 and its aggressive variant
S19 have been previously described [27]. All cell lines were
maintained in RPMI 1640 complete medium supplemented with
8% (v/v) FCS, 2 mM L-glutamine, 10 mM Hepes buffer, 1 mM
sodium pyruvate and 0.075% sodium bicarbonate. All cell culture
products were purchased from Life Technologies (Burlington, ON,
Canada). Anti-cleaved PARP-1 antibody was purchased from
Epitomics (Burlingame, CA); anti-b-actin antibody was purchased
from Sigma-Aldrich (St. Louis, MO); anti-EGR-1 antibody was
purchased from Santa Cruz (CA, USA); anti-human galectin-7
monoclonal antibody was purchased from R & D Systems; methyl
[3H]thymidine was purchased from Perkin Elmer (Waltham, MA);
cell culture lysis reagent (CCLR) and passive lysis buffer were
purchased from Promega (Madison, WI); RIPA lysis buffer was
purchased from Thermo Scientific (Rockford, USA); and buffered
formaldehyde solution was purchased from Fisher Scientific
(Toronto, ON). All other reagents were purchased from Sigma-
Aldrich unless otherwise indicated.
RNA Isolation and Semiquantitative PCR
Total RNA was isolated from tissues using Trizol reagent
according to the manufacturer’s instructions (Invitrogen Canada,
Inc., Burlington, ON). Briefly, total RNA (2 mg) was reverse
transcribed using Omniscript reverse transcriptase (Qiagen,
Mississauga, ON) and PCR amplified using the following
conditions: 94uC for 0.5 min, 58uC for galectin-7 and b-actin or
60uC for Egr-1 for 1 min, and 72uC for 1 min. Then, a final
extension step was performed at 72uC for 10 min. The primers
used for PCR amplification were (59-CCATGTCTGCT-AC-
CCATCAC-39; in exon 2) for sense murine galectin-7 and (59-
GCTTAGAA-GATATTCAATGAATGC-39; in exon 5) for
antisense; (59-TAATAGCAGCAGCAGCA-CCAGC-39) for sense
murine EGR-1 and (59-GTCGTTTGGCTGGGATAACTCG-
39) for antisense, and (59-CATGGATGACGATAT-
CGCTGCGC-39) for sense b-actin and (59-
GCTGTCGCCACGCTCGGTCAGGAT-39) for antisense. Am-
plification was carried out in a thermal cycler (model PTC-100,
MJ Research, Watertown, MA) using equal amounts of RNA that
was reverse transcribed and amplified by PCR for 35 cycles with
gene-specific primers. Each amplification step was performed in
the linear range for each gene. b-actin mRNA was amplified as an
internal control by RT-PCR using specific primers. Amplified
products were analyzed by electrophoresis on 1.2% agarose gels
for galectin-7 and b-actin or 1.8% gels for Egr-1 using Sybr Safe
staining and UV illumination.
Generation of Stable Transfectants Expressing Luciferase
and Galectin-7
To obtain stable B16F1-Luc transfectants expressing the
luciferase reporter gene under the control of the SV40 promoter,
B16F1 cells were co-transfected with linearized pGL3-(SV40)
vector (Promega) and the pSra vector that conferred puromycin
resistance. After 48 h of culture in complete medium, transfected
cells were grown in complete medium containing 2 mg/mL of
puromycin before individual colonies were selected and expanded.
Clones expressing constitutively high levels of luciferase (clones #1
and #9) were then used to generate stable transfectants expressing
constitutively high levels of galectin-7. For this purpose, we used
the pRc-CMV2-galectin-7 vector encoding the murine galectin-7
gene (GenBank accession no. AF 331640). Individual colonies
were selected, expanded and assayed for galectin-7 expression by
RT-PCR, ELISA and confocal microscopy. Control transfectants
were generated using the empty pSra vector, as described [20].
Proliferation Assay
Three clones of B16F1 cells overexpressing galectin-7 (B16F1-
G7 #5, 10 and 14) and three control cell lines (B16F1-sra #1, 2
and 3) were seeded at 26103 cells/well in 96-well culture plates.
Once the cells were confluent, quercetin was added at 10 mg/mL
(dissolved in DMSO) for 72 h. In control wells, 1% DMSO
solution was added. DNA synthesis was assayed by adding 1 mCi
of methyl-[3H]thymidine/well and incubating the cells for 16 h.
Radioactivity was measured after adding a scintillation cocktail
using a scintillation counter (Trilux, 1450 microbeta, Wallac). The
experiment was performed in triplicate and repeated three times.
Luciferase Assay
Luciferase activity in cell lines and tissues was measured as
previously described [28]. Briefly, for ex vivo imaging, mice were
injected i.p. with 150 mg/kg of D-luciferin. Ten minutes later, the
mice were sacrificed, and lungs were collected. After imaging,
lungs were homogenized in cell culture lysis reagent (CCLR), snap
frozen in liquid nitrogen and thawed at 37uC before luciferase
assays. For cell lines, B16F1 transfectant cells (106 cells) were lysed
in 100 mL of CCLR containing phenylmethylsulfoxide at 4uC for
1 h and then vortexed for 30 sec. After centrifugation for 20 min
at 4uC, the protein concentration of the supernatant was measured
by the Bradford method. Equal amounts of protein were used to
determine luciferase activity. Luciferase activity was measured
using the Luciferase Assay System and a Lumat LN 9507
Luminometer (Berthold Technologies, Oak Ridge, TN).
Tumorigenic and Metastatic Assays
Male or female C57BL/6 mice and galectin-7-deficient mice
(KOG7) (6 to 8 weeks old) were injected subcutaneously (s.c.) into
the left flank with 56104 B16F1 cells. Animals were monitored
periodically for tumor growth, which did not exceed a volume of
2500 mm3. The length (L) and width (W) of the tumor were
measured using calipers fitted with a vernier scale, and the size of
the tumor was calculated using the formula L26W60.4. When the
maximum tumor volume was reached, mice were sacrificed, and
the tumors were divided and frozen for PCR analysis or fixed in a
buffered formaldehyde solution for immunohistochemistry (IHC).
To induce the dissemination of B16F1 melanoma cells in the lung,
male or female C57BL/6 mice (6 to 8 weeks old) were injected in
the tail vein with 26105 B16F1 luciferase transfectant cells that
were either control or overexpressed galectin-7. Animals were
monitored periodically for clinical signs of tumor growth. When
moribund or at a specific time, the mice were sacrificed, and lungs
were collected and examined by ex vivo imaging. Tissues were
homogenized in CCLR for luciferase assays as described above.
Immunohistochemistry
Primary and metastatic lung tumors were fixed and processed
for IHC analysis as described previously [22]. Briefly, 3-mm-thick
sections were prepared from each tissue sample. Immunostaining
reactions for galectin-7 were carried out using the Discovery XT
automated immunostainer (Ventana Medical Systems, Tucson,
Galectin-7 in Melanomas
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Figure 2. Increased galectin-7 expression in B16F1 primary tumors and lung metastases. Primary tumors were collected at necropsy 18
days after the subcutaneous injection of B16F1 cells (56104 cells) in C57BL/6 (WT) and galectin-7-deficient mice (KOG7). (A) RT-PCR analysis of
galectin-7 mRNA expression in two B16F1 primary tumors from WT and KOG7 mice in comparison with the B16F1 cell line. Actin was used as a
loading and specificity control. B) Immunohistochemistry for galectin-7 in normal skin (i, ii) and B16F1 primary tumors (iii, iv) in WT and KOG7 mice.
These galectin-7-positive structures located in the suprabasal epidermis have been reported before and likely represent suprabasal keratinocytes,
which are known to express galectin-7 constitutively [13]. Control stained without HRP and in absence of Abs did not show any detectable staining in
both wt and KOG7 mice. C) Immunohistochemistry for galectin-7 in a lung collected 20 days post-injection from one KOG7 mouse injected
intravenously via the tail vein with B16F1 cells (26105 cells) in comparison with a normal lung. Scale bars in all immunohistochemistry images
represent 600 mM.
doi:10.1371/journal.pone.0063307.g002
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AZ). Deparaffinized sections were incubated in cell conditioning
solution (pH 8.0) for antigen retrieval and then stained for 60 min
with an anti-human galectin-7 monoclonal antibody at a 1:150
dilution. The slides were counterstained with hematoxylin and
bicarbonate. Each section was scanned at a high resolution
(Nanozoomer, Hammamatsu Photonics K.K). A total of 13
human malignant melanomas and 47 nevus were analyszed from
samples obtained with a written informed consent and with the
approval of the research ethics committee of the research center at
the Centre Hospitalier de l’Universite´ de Montre´al.
ELISA Assays
Cells were lysed with RIPA lysis buffer at 4uC for 1 h and then
centrifuged at 12000 rpm for 20 min at 4uC. Protein concentra-
tions were measured by the Bradford method. Amounts of 100 or
200 mg of total protein per well were analyzed using the murine
Figure 3. Validation of B16F1 transfectants overexpressing luciferase and/or galectin-7. A) RT-PCR analysis for galectin-7 mRNA
expression in transfectant cells overexpressing galectin-7 with or without luciferase in comparison with a control B16F1 cell line (F1). The aggressive
murine lymphoma cell line S19 (+) was used as a positive control. Actin was used as a loading and specificity control. B) Luciferase assay of three
B16F1 transfectant cell lines overexpressing luciferase and cotransfected with pRc-CMV2-galectin-7 in comparison with the control B16F1 cell line. C)
Confocal microscopy for galectin-7 in control B16F1 cells (iii) and galectin-7 transfectant cells (G7#5) (iv); these cells were also visualized (i, ii).
doi:10.1371/journal.pone.0063307.g003
Galectin-7 in Melanomas
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galectin-7 ELISA kit (R & D Systems) according to the
manufacturer’s instructions. For supernatant analysis, aliquots of
46104, 1.36103 and 450 cells were plated in 96 wells plate in
100 mL of culture media and incubated for 24, 48 and 72 h
respectively to obtain 100% confluent cells in each well. The total
volume of supernatant was used for the ELISA assay.
Motility Assay
Confluent cultures grown in six-well culture plates were
wounded with a 200 mL pipette tip (time 0) and incubated for
16 h. The wells were inspected with an inverted light microscope
(Nikon eclipse TE2000-U) using a 10X objective. Images were
captured using a coolSNAP HQ camera and analyzed using the
Metamorph software (Universal Imaging Corporation).
Transient Transfection
B16F1 cells and cells from a mix of three B16F1-G7 clones
(G7#5, #10, and #14) were plated at a concentration of 105 cells
per well in six-well plates and incubated at 37uC overnight.
Thereafter, cells were co-transfected with 0.2 mg of PGL3-EGR-1
reporter construct and 0.2 mg of pRLSV40-Renilla vector, for
transfection control, using 5 mL of Lipofectamine 2000 reagent
Figure 4. Effect of galectin-7 on B16F1 cell migration. A) Images of the motility assay after the wounding of confluent B16F1 cells
overexpressing galectin-7 (B16-G7) or controls (B16-Sra) at T = 0 and T= 16 hr. A mixture of three clones of B16F1-G7 was used (G7 #5, 10 and 14). B)
Representative graph of the results obtained in (A).
doi:10.1371/journal.pone.0063307.g004
Galectin-7 in Melanomas
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according to the manufacturer’s protocol (Invitrogen). After 24 h,
transfected cells were treated with increasing concentrations of
quercetin (0–100 mg/mL) for 24 h. Cells were lysed with 100 mL
of passive lysis buffer containing PMSF at 4uC for 1 h and
centrifuged for 20 min at 4uC. Equal amounts of protein were
analyzed by the Dual-Luciferase Assay system according to the
manufacturer’s instructions (Promega).
Statistical Data Analysis
Data are presented as means 6 SD. Student t test was used to
test for statistical significance that was established at p,0.05.
Results
Galectin-7 Expression in Human Melanoma Tissues
We first conducted an in silico analysis of galectin-7 expression
using datasets from the Gene Expression Omnibus (GEO)
repository of the National Center for Biotechnology Information
(NCBI). For this purpose, we examined a dataset of microarray
data obtained from the profiling of 45 malignant melanomas and
18 nevi (GDS1375) [29]. These data showed that galectin-7 was
detected at the mRNA level in all biopsies of normal skin (n = 7)
and in most biopsies collected from patients with nevi (17/18)
(Fig. 1a). In biopsies obtained from patients with malignant
melanomas, galectin-7 expression was relatively rare (9/45)
(Fig. 1b). Similar expression patterns were also observed for
benign versus malignant melanoma in a dataset collected from the
whole-genome profiling of the melanoma progression pathway
(GDS1989) [30]. Low expression levels of galectin-7 were also
observed in both human and mouse malignant melanoma cell
lines [31] (Fig. 1c and Figure S1). Interestingly, however, we
found that galectin-7 can be upregulated in B16 melanoma cells
that had been injected subcutaneously into normal C57BL/6
syngeneic mice (Fig. 2a). IHC staining of B16 tumors in galectin-
7-deficient (KOG7) mice confirmed that galectin-7 expression in
the B16 tumors was not due to expression by surrounding stromal
cells (Fig. 2b). Interestingly, a stronger galectin-7 staining was
observed in KOG7 mice as compared to WT mice. The reason for
such a difference is unclear at present. This upregulation of
galectin-7 in B16 melanoma cells in vivo was also observed in lung
biopsies of KOG7 mice injected i.v. with B16 cells (Fig. 2c).
Generation of a B16 Melanoma Cell Line Constitutively
Expressing Galectin-7
Because overexpression of galectin-7 is known to regulate tumor
growth and metastasis in multiple tumor cell types, we next
investigated whether galectin-7 could modulate the growth of
primary tumors and the dissemination of metastasis. For this
purpose, we generated a series of stable B16 transfectants
constitutively expressing galectin-7 at both the mRNA and protein
levels (Fig. 3). The transfectants were also co-transfected with an
expression vector encoding the firefly luciferase gene to facilitate
in vivo follow-up of metastases to the lung. As previously reported,
galectin-7 expression was restricted to the intracellular compart-
ment and was not detected in the cultured supernatant of B16
transfectants (Fig. 3c and Figure S2).
Galectin-7 Reduces the Motility, Induces Resistance to
Apoptosis and Increases egr-1 (Early Growth Response
Protein 1) in B16 Melanoma Cells
The expression of galectin-7 in B16 cells significantly reduced
their cellular motility (Fig. 4). While galectin-7 did not affect the
in vitro proliferation rate of the cells, it did inhibit their sensitivity to
apoptosis induced by quercetin in a dose-dependent manner
(Fig. 5 and Figure S3). This effect of galectin-7 on quercetin-
induced apoptosis was concomitant with its ability to upregulate
both the mRNA and protein levels of EGR-1, consistent with
previous results obtained in human colon carcinoma cell line [32].
EGR-1 is a master regulator that plays an important role in a
variety of cellular processes in cancer cells [33]. The ability of
galectin-7 to increase EGR-1 at the transcriptional level in B16F1
cells was confirmed using a reporter vector encoding the egr-1
promoter (Fig. 5d).
Figure 5. Effect of quercetin on B16F1 cells overexpressing
galectin-7 on apoptosis and EGR-1 expression. B16F1 cells
overexpressing galectin-7 (+) or controls (–) were treated with various
doses of quercetin. A) Apoptotic sensitivity was analyzed by western
blotting for cleaved PARP-1 detection. B) RT-PCR analysis of galectin-7
and EGR-1 mRNA expression. C) Western blot analysis for EGR-1
detection, 293 cells transfected with EGF were used as a positive
control. Actin was used as a loading and specificity control. D) Dual
luciferase assay of B16F1 transfectant cells overexpressing galectin-7
(%) or controls (&) co-transfected with luciferase reporter plasmids
with an EGR-1 promoter and pRLSV40-Renilla vector as a transfection
control and treated with various doses of quercetin for 24 h. A mixture
of three clones of B16F1-G7 was used (G7 #5, 10 and 14) for all of these
experiments.
doi:10.1371/journal.pone.0063307.g005
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In vivo Growth of B16 Cells Expressing High Levels of
Galectin-7
We next investigated whether galectin-7 could modulate the
tumor progression of B16 melanoma cells. For this purpose, we
first compared the growth of B16 cells expressing high levels of
galectin-7 (B16-G7) with control cells (B16-Sra). Our results
showed that mice injected with B16 cells had similar survival rates
regardless of galectin-7 expression (2662.3 days (n = 12) for
galectin-7-expressing cells vs. 25.963.7 days (n = 12) for controls)
(Fig. 6a). This result was observed in independent experiments
using either 16104 or 56104 cells (data not shown). To study the
effect of galectin-7 on melanoma metastasis, we used genetically
engineered B16F1 cells overexpressing luciferase. This cell line
model facilitates cancer cell detection in target organs with a
luciferase assay or the ex vivo bioluminescence imaging of organs.
Although we observed a time-dependent increase in the metastatic
Figure 6. Effect of galectin-7 in B16F1 cells on survival and metastasis in lungs. A) Survival curve of C57BL/6 mice injected i.v. with B16F1
transfectant cells overexpressing galectin-7 (%) or controls (¤) (26105 cells) (n = 8210). B) Luciferase assay of lungs of C57BL/6 mice sacrificed at 9,
12, 15 or 18 days after the i.v. injection of a mixture of B16F1 luciferase transfectant cells overexpressing galectin-7 (+) or control (–) (n = 328). Normal
lungs were used as a negative control (T: 0; n = 2). C) Ex vivo imaging of a lung metastasis, as seen in (B), of B16F1 cells overexpressing galectin-7 (iii
and v) or control cells (ii and iv) at 9 and 18 days in comparison with control lungs (i).
doi:10.1371/journal.pone.0063307.g006
Galectin-7 in Melanomas
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load in the lung, the number of metastases was similar in mice
injected with galectin-7 transfectant cells compared with those
injected with control cells (Fig. 6b and 6c).
Discussion
Galectin-7 is normally expressed in stratified epithelia, most
notably in the skin epidermis. In cancer, its expression is often
altered, although its role in cancer biology is debated. A number of
indications have suggested that galectin-7 may potentially be
important in melanoma proliferation, invasion, and metastasis.
Like other members of the galectin family, galectin-7 has been
shown to either positively or negatively modulate apoptosis and
tumor growth [34]. In colon cancer, for example, galectin-7 has an
anti-tumorigenic function [15], in contrast to its pro-tumorigenic
function reported in lymphoma, breast cancer, squamous cell
carcinoma of the tongue and esophagus, and thyroid malignancies
[20-22,35–37]. In skin cancer, a recent study has shown that
galectin-7 is induced during neoplastic transformation of the skin
following exposure to cypermethrin, a highly carcinogenic
insecticide used for agricultural and domestic applications [38].
Because melanoma represents one of the most dangerous forms of
skin cancer, we investigated the role of galectin-7 in melanoma. In
the present work, we have shown that 1) galectin-7 is rarely
expressed in biopsies of malignant melanoma, 2) galectin-7
reduces the motility of B16F1 cells, and 3) galectin-7 increases
the resistance of B16F1 cells to apoptosis and the expression of
EGR-1. We also found that overexpression of galectin-7 is
insufficient to modulate the growth of primary tumors or the
dissemination of B16 melanoma cells to the lung.
Our data showing that galectin-7 reduces the motility of
melanoma cells are novel and worth investigating further in the
context of the ability of Bcl-2 to bind galectin-7 [39]. Although the
functional relevance of such an interaction is likely to explain the
ability of galectin-7 to modulate apoptosis, it could also be
important for cell motility because as suggested by a recent study
showing that cytoplasmic Bcl-2 inhibits cell motility and enhances
F-actin polymerization during cell spreading [40]. Moreover,
Villeneuve et al. [39] have shown that in keratinocytes, galectin-7
colocalizes with cortactin, an actin-binding protein implicated in
membrane ruffle formation. It is noteworthy, however, that
reduced in vitro motility did not affect the number of metastases
to the lung, suggesting caution when assigning correlations
between in vitro and in vivo observations. Although cell motility
and/or EGR-1 are likely to be important in tumor progression, it
is logical to assume that their relative importance is tumor and
context dependent.
In silico analysis of public datasets has shown that galectin-7
mRNA is detected in most if not all nevi. Our IHC data and the
fact that galectin-7 is constitutively expressed at high levels in skin
epidermis suggest that such signal likely represents that presence of
epithelial cells in the biopsies of nevi. Such explanation may also
be true for malignant melanoma. These results emphasize the risk
of surrounding tissue contamination when performing analysis of
biopsies. Nevertheless, our results showing that B16 cells do
express galectin-7 when transplanted in vivo leaves open the
possibility that in rare cases, galectin-7 could be expressed in
malignant melanoma cells. Future IHC analysis on normal
melanocytes and in a larger number of biopsies of nevus and
melanoma are needed to determine the utility of galectin-7 as a
predictive biomarker in melanom. Our in vivo results using stable
transfectants overexpressing galectin-7 suggest, however, that if
indeed galectin-7 can be found in rare cases of melanoma, it
probably plays a very limited role in tumor growth and apoptosis.
The importance of galectin-7 in melanoma is thus very distinct
from what has been observed in other types of epithelial cancer.
Supporting Information
Figure S1 Expression of galectin-7 in murine and
human melanoma cell lines. Galectin-7 expression in the
aggressive variant B16F10 murine melanoma cells in comparison
to the parental cell line B16F1 analyzed by A) RT-PCR for
galectin-7 mRNA expression (Actin was used as loading and
specificity control) and B) ELISA assay for galectin-7 concentra-
tion in comparison with 164T2 non aggressive lymphoma cells
and its aggressive variant S19. C) ELISA assay for galectin-7
concentration in human melanoma cell lines (888mel, 537mel,
SK23 and Mel-FB) in comparison to MDA-MB-468 breast cancer
cell line as positive control.
(TIFF)
Figure S2 ELISA assay for galectin-7 concentration in
culture supernatant of B16F1 tranfectant cells overex-
pressing (%) or not (&) galectin-7 after 24, 48 and 72
hours of incubation. Lysed cells from this experiment were
used as positive control.
(TIFF)
Figure S3 Cellular proliferation was analyzed by thy-
midine incorporation after 72 hours of quercetin (10 mg/
ml) treatment in B16F1 transfectant cells overexpressing
(%) or not (&) galectin-7. Results are representative of three
independent experiments.
(TIFF)
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